{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:31:22Z","timestamp":1787495482734,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012739","name":"Zogenix Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.yebeh.2021.108212","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T12:51:16Z","timestamp":1627908676000},"page":"108212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth"],"prefix":"10.1016","volume":"122","author":[{"given":"Antonio","family":"Gil-Nagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berten","family":"Ceulemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Wirrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orrin","family":"Devinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Nabbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly G.","family":"Knupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scott Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Polster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold R.","family":"Gammaiton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Farfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Galer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.108212_b0005","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108212_b0010","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2021.108212_b0015","unstructured":"Sullivan J, Lagae L, Cross JH, Devinsky O, Guerrini R, Knupp KG, et al. Fenfluramine (FINTEPLA) in Dravet syndrome: results of a third randomized, placebo-controlled clinical trial (Study 3) [poster]. Presented at: American Epilepsy Society 2020. Virtual."},{"issue":"suppl 2","key":"10.1016\/j.yebeh.2021.108212_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108212_b0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.seizure.2016.10.014","article-title":"From genotype to phenotype in Dravet disease","volume":"44","author":"Gataullina","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108212_b0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yebeh.2017.06.031","article-title":"Dravet syndrome: characteristics, comorbidities, and caregiver concerns","volume":"74","author":"Villas","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108212_b0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.seizure.2017.09.021","article-title":"Growth and endocrine function in children with Dravet syndrome","volume":"52","author":"Eschbach","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108212_b0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.0000000000002859","article-title":"Motor neuropathy contributes to crouching in patients with Dravet syndrome","volume":"87","author":"Gitiaux","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108212_b0045","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0140-6736(73)90325-5","article-title":"Fenfluramine in the treatment of obesity","volume":"1","author":"Stunkard","year":"1973","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108212_b0050","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/epi.16722","article-title":"Fenfluramine HCl (Fintepla\u00ae) provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study","volume":"61","author":"Sullivan","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108212_b0055","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1750-1172-8-176","article-title":"Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy","volume":"8","author":"Nabbout","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2021.108212_b0060","unstructured":"World Health Organization. The WHO child growth standards. 2017; http:\/\/www.who.int\/childgrowth\/en\/. Accessed October 2, 2017."},{"key":"10.1016\/j.yebeh.2021.108212_b0065","unstructured":"Centers for Disease Control and Prevention. Clinical growth charts. 2017; https:\/\/www.cdc.gov\/growthcharts\/clinical_charts.htm. Accessed October 3, 2017."},{"key":"10.1016\/j.yebeh.2021.108212_b0070","doi-asserted-by":"crossref","first-page":"e1310","DOI":"10.1542\/peds.2015-1807","article-title":"Incidence of Dravet syndrome in a US population","volume":"136","author":"Wu","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.yebeh.2021.108212_b0075","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yebeh.2014.12.028","article-title":"The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome","volume":"44","author":"Aras","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108212_b0080","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1177\/0883073811406982","article-title":"Long-term open-label study of adjunctive topiramate in infants with refractory partial-onset seizures","volume":"26","author":"Puri","year":"2011","journal-title":"J Child Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108212_b0085","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/dmcn.13704","article-title":"Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study","volume":"60","author":"Myers","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.108212_b0090","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/oby.2003.78","article-title":"Predictors of weight loss in adults with topiramate-treated epilepsy","volume":"11","author":"Ben-Menachem","year":"2003","journal-title":"Obes Res"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502100473X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502100473X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:40:29Z","timestamp":1761504029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502100473X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":18,"alternative-id":["S152550502100473X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108212","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108212"}}